Chemotherapy for breast cancer progresses to liver metastases after surgery and systemic treatment

被引:3
|
作者
Yin, Tao [1 ]
Nie, Lei [1 ]
Wu, Dongde [1 ]
Liu, Baozhen [2 ]
Feng, Yaojun [3 ]
Wu, Xinhong [3 ]
Luo, Chenggang [1 ]
Liang, Jianjun [4 ]
机构
[1] Hua Zhong Univ Sci & Technol, Hubei Canc Hosp, Dept Hepatobiliary & Pancreat Surg, Wuhan 430079, Peoples R China
[2] Sch Hosp Wuhan Text Univ, Wuhan 430079, Peoples R China
[3] Hua Zhong Univ Sci & Technol, Hubei Canc Hosp, Dept Breast Canc Surg, Wuhan 430079, Peoples R China
[4] First Hosp Wuxue Cty, Huanggang 430079, Peoples R China
关键词
Unresectable breast cancer liver metastases (UBCLM); hepatic arterial infusion chemotherapy/portal vein infusion chemotherapy (HAIC/PVIC); prognosis; HEPATIC ARTERIAL INFUSION; RESECTION; CHEMOEMBOLIZATION;
D O I
10.21037/tcr.2019.12.59
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: This study aims to evaluate the effectiveness of hepatic arterial infusion chemotherapy/portal vein infusion chemotherapy (HAIC/PVIC), transcatheter hepatic arterial chemoembolization (TACE) and transcatheter arterial embolization (TAE) for unresectable breast cancer liver metastases (UBCLM). Methods: The present study included 57 patients. These patients were randomly divided into three groups (n=19, each): HAIC/PVIC group, TACE group and TAE group. Patients in the HAIC/PVIC group were treated with the same systemic chemotherapy regimen previously received by infusion through an intra-arterial and portal vein catheter. Patients in the TACE group received cyclophosphamide, epirubicin and 5-fluorouracil, and embolization. Patients in the TAE group were only treated with embolization. Results: The median number of treatments was 6 (range, 3-13) in the HAIC/PVIC group, 5 (range, 4-9) in the TACE group, and 6 (range, 4-8) in the TAE group. The 1-, 2- and 3-year survival rates for these groups were 18/19 (94.7%), 14/19 (73.7%) and 11/19 (57.9%), 14/19 (73.7%), 9/19 (47.4%) and 8/19 (42.1%), and 8/19 (42.1%), 4/19 (21.1%) and 0/19 (0%), respectively. The median overall survival from the original breast cancer diagnosis was 88 (range, 11-133), 75 (range, 9-115), and 49 (range, 10-64) months in the HAIC/PVIC, TACE and TAE groups, respectively. Grade I-II and grade III-IV bone marrow suppression was observed in 12/19 (63.2%) and 3/19 (15.8%) patients in the HAIC/PVIC group, respectively, in 17/19 (89.5%) and 5/19 (26.3%) patients in the TACE group, respectively, and in 0/19 (0%) and 0/19 (0%) patients in the TAE group, respectively. Conclusions: HAIC/PVIC with the same regional chemotherapy regimen of the original systemic treatment is feasible, and can benefit patients with UBCLM, who have progressed on prior systemic therapies.
引用
收藏
页码:993 / 1000
页数:8
相关论文
共 50 条
  • [21] Hepatic Arterial Infusion Chemotherapy for Liver Metastases From Pancreatic Cancer After Surgery
    Tajima, H.
    Gabata, R.
    Okazaki, M.
    Ohbatake, Y.
    Shimbashi, H.
    Nakanuma, S.
    Makino, I.
    Miyashita, T.
    Ohta, T.
    PANCREAS, 2019, 48 (10) : 1530 - 1531
  • [22] Successful Treatment with Hepatic Arterial Infusion Chemotherapy in a Breast Cancer Patient with Multiple Liver Metastases Who Declined Systemic Therapy
    Masuda, Takaaki
    Niizeki, Osamu
    Niizeki, Takashi
    Fujiyoshi, Kenji
    Ando, Yuki
    Niizeki, Hiroshi
    Mimori, Koshi
    CASE REPORTS IN ONCOLOGY, 2021, 14 (03): : 1261 - 1265
  • [23] Local Treatment of Breast Cancer Liver Metastases
    Sadot, E.
    Yee, L. Ser
    Petre, E.
    Sofocleous, C.
    Hudis, C.
    Goenen, M.
    Kingham, T.
    Allen, P.
    Solomon, S.
    Fong, Y.
    DeMatteo, R.
    Jarnagin, W.
    D'Angelica, M.
    ANNALS OF SURGICAL ONCOLOGY, 2014, 21 : S98 - S98
  • [24] Internal radiation treatment of liver metastases from colorectal cancer with concomitant systemic radiosensitising chemotherapy
    Sharma, R.
    van Hazel, G.
    Blanshard, K.
    Price, D.
    Bower, G.
    Shannon, J.
    Gibbs, P.
    Berry, D.
    Morgan, B.
    Steward, W.
    ANNALS OF ONCOLOGY, 2006, 17 : 78 - 78
  • [25] Chemotherapy and surgery: new perspectives on the treatment of unresectable liver metastases
    Adam, R
    ANNALS OF ONCOLOGY, 2003, 14 : 13 - 16
  • [26] Systemic treatment of brain metastases from breast cancer
    Taillibert, S.
    Conforti, R.
    Bonneterre, J.
    Bachelot, T.
    Le Rhun, E.
    Bernard-Marty, C.
    CANCER RADIOTHERAPIE, 2015, 19 (01): : 36 - 42
  • [27] SYSTEMIC ADJUVANT CHEMOTHERAPY AFTER RESECTION OF COLORECTAL CANCER METASTASES
    Brandi, G.
    Derenzini, E.
    Pantaleo, M. A.
    Di Battista, M.
    Ravaioli, M.
    Ercolani, G.
    Grazi, G. L.
    Fanello, S.
    Di Marco, M.
    Nobili, E.
    Hakim, R.
    Poggi, R.
    Palmerini, E.
    Biasco, G.
    ANNALS OF ONCOLOGY, 2004, 15 : 66 - 66
  • [28] Systemic treatment of liver metastases from colorectal cancer
    Stein, Alexander
    Schmoll, Hans-Joachim
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2013, 5 (03) : 193 - 203
  • [29] Systemic treatment of orbital metastases from breast cancer
    Jagiello-Gruszfeld, AI
    Pienkowski, TJ
    Rudnicka, H
    Huczynska-Szubert, E
    INTERNATIONAL JOURNAL OF CANCER, 2002, : 196 - 196
  • [30] Systemic chemotherapy as a main strategy for liver metastases from gastric cancer
    W. Zhang
    Y. Yu
    Y. Fang
    Y. Wang
    Y. Cui
    K. Shen
    T. Liu
    Clinical and Translational Oncology, 2015, 17 : 888 - 894